When do device-based or injectable treatments start to work?
When do device-based or injectable treatments start to work? Improvements are usually gradual. With vaginal laser/radiofrequency, comfort tends to build over several weeks after each session; most plans include 2–3 sessions spaced 4–8 weeks apart. With injectables (platelet-rich plasma or polynucleotides), changes also accumulate over weeks as tissues settle. Results vary by placement, symptom pattern (e.g., vestibular micro-tears, dyspareunia), and foundations like moisturiser and lubricant. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
When do device-based or injectable treatments start to work? For most people with genitourinary syndrome of menopause (GSM)—also called vaginal atrophy—device-based and injectable options produce gradual changes rather than immediate relief. This is because they act on tissue quality and mechanics over time, while the underlying biology of GSM (low oestrogen, thinner epithelium, higher vaginal pH, fewer protective lactobacilli) persists unless you also use local hormonal therapy. Your timelines depend on the specific technology, how precisely it targets your symptoms (e.g., entrance-focused micro-tears vs general canal dryness), and whether basics like a scheduled moisturiser and a compatible lubricant are in place.
Vaginal laser or radiofrequency (RF): what to expect. Energy devices (fractional CO2/Er:YAG lasers or RF) aim to nudge collagen remodelling and blood flow in the mucosa/submucosa. Many notice small day-to-day wins—less “sandpaper” friction on walking/cycling, easier speculum tolerance—within several weeks after a session. Because remodelling unfolds slowly, most plans use 2–3 sessions spaced 4–8 weeks apart, with comfort building cumulatively and settling further between visits. It’s normal for improvements to feel subtle before they consolidate; keeping foundations steady in between sessions helps you judge genuine change.
Injectables (PRP or polynucleotides): what to expect. Platelet-rich plasma (PRP) concentrates your own platelets/growth factors to encourage local repair and blood flow. Polynucleotides (highly purified DNA fragments) are biostimulatory and water-binding, used to condition superficial tissue and improve slip. When they help, people often report fewer “paper-cut” splits at the posterior fourchette and calmer insertional sting over several weeks. As with devices, care is usually delivered as a short series (often 2–3 sessions, 4–8 weeks apart) with a reassessment window to decide on maintenance or whether foundations alone now suffice.
Placement matters more than labels. If the vestibule (entrance) is your hotspot, internal-only approaches can miss the sore ring. With local therapies, add fingertip placement to the vestibule; with injectables, clinicians should target symptomatic points superficially; with devices, protocols should carefully address the entrance when appropriate and safe. Accurate placement often explains why one person improves within weeks while another feels little change.
Foundations accelerate perceived benefit. A scheduled vaginal moisturiser (many prefer hyaluronic-acid gels) 2–4 times weekly reduces day-to-day friction quickly. A compatible personal lubricant during higher-friction moments is essential: water-based (versatile, condom-friendly), silicone-based (long glide for dyspareunia with a tender vestibule), or oil-based (rich feel but may degrade latex condoms/toys). If acceptable, local vaginal oestrogen (or vaginal DHEA) supports epithelial maturity and healthier pH over 2–6 weeks, making any device/injectable gains easier to feel and sustain.
Real-life pacing so you can tell what’s working. Add one “big” change at a time and build in a pause. A helpful structure is laid out in our pathway: see how treatment steps are sequenced. If you also want to map sessions, reviews and budgets, see treatment prices. Typical milestones: moisturiser/lubricant → immediate to 2 weeks; local oestrogen/DHEA → 2–6 weeks and building; device session → several weeks after each visit, cumulative across the series; injectables → several weeks after each session, cumulative across 2–3 sessions.
When timelines feel slower than expected. Re-check diagnosis and co-drivers. “Dryness” can mask BV/thrush, UTIs, contact dermatitis, lichen sclerosus, or vestibulodynia. If deep pelvic pain dominates, consider endometriosis/adenomyosis pathways rather than escalating surface treatments. If protective pelvic floor guarding developed after painful sex, add pelvic health physiotherapy and, if helpful, graded dilators; neither devices nor injectables relax muscles on their own.
Setting expectations. Improvements—when they occur—are usually gradual and partial. Some people feel calmer day-to-day movement after the first visit; others only after the second. Results are not permanent and may soften over months, which is why review points (e.g., 6–12 weeks after a series) are baked into most plans. The goal is a personalised, lowest effective maintenance routine once you’re comfortable.
Clinical Context
Who tends to notice earlier change? People whose main issue is entrance-focused burning or micro-tears and who target the vestibule precisely—whether with fingertip-applied local oestrogen, a silicone-based lubricant for long glide, or superficial injectables. Those with general canal dryness often feel a steadier build across a device series.
Who may see slower progress? Anyone with ongoing irritants (fragranced washes/liners, tight synthetic kit, chlorine without rinsing), untreated infections, or mis-targeted care (internal-only when the vestibule is the hotspot). If symptoms plateau, pause procedures and reassess technique and diagnosis before adding more.
Next steps. Keep cleansing gentle (lukewarm water; bland emollient as a soap substitute), wear breathable underwear, schedule moisturiser 2–4 times weekly, and use generous lubricant early (don’t wait for sting). If acceptable, add local vaginal oestrogen or DHEA to support biology. Use symptom diaries to track urine-sting, fissures and dyspareunia at 6–12-week reviews.
Evidence-Based Approaches
Foundations and first-line care (UK): Plain-English self-care and when to seek help are outlined by the NHS for vaginal dryness. The NICE Menopause Guideline (NG23) advises offering vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life.
Comparators with robust evidence: Systematic reviews in the Cochrane Library show local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, tablets/pessaries and rings; effects build over weeks and persist with continued use.
Pathophysiology detail: Peer-reviewed overviews indexed on PubMed explain GSM mechanisms (thinner epithelium, higher pH, reduced lactobacilli), clarifying why device/injectable responses emerge over weeks rather than days and why combining with local therapy often helps.
Prescribing/product information: UK information and cautions for local vaginal oestrogens and prasterone (DHEA) are available in the British National Formulary (BNF), supporting safe selection and placement (including vestibule targeting with creams).
Applying the evidence: Follow a stepped, review-based pathway: foundations → local therapy if needed → consider devices or injectables only when appropriate, with 4–8 week spacing and clear goals. Use precise placement (especially at the vestibule) and maintain basics to help improvements appear sooner and last longer.